A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

Authors:
Address: Center of Infectious Disease and Vaccinology, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA.
Journal:


Publication:
Free Text: A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

abstract

Ebola hemorrhagic fever is an acute and often deadly disease caused by Ebola virus (EBOV). The possible intentional use of this virus against human populations has led to design of vaccines that could be incorporated into a national stockpile for biological threat reduction. We have evaluated the immunogenicity and efficacy of an EBOV vaccine candidate in which the viral surface glycoprotein is biomanufactured as a fusion to a monoclonal antibody that recognizes an epitope in glycoprotein, resulting in the production of Ebola immune complexes (EICs). Although antigen-antibody immune complexes are known to be efficiently processed and presented to immune effector cells, we found that codelivery of the EIC with Toll-like receptor agonists elicited a more robust antibody response in mice than did EIC alone. Among the compounds tested, polyinosinic:polycytidylic acid (PIC, a Toll-like receptor 3 agonist) was highly effective as an adjuvant agent. After vaccinating mice with EIC plus PIC, 80% of the animals were protected against a lethal challenge with live EBOV (30,000 LD(50) of mouse adapted virus). Surviving animals showed a mixed Th1/Th2 response to the antigen, suggesting this may be important for protection. Survival after vaccination with EIC plus PIC was statistically equivalent to that achieved with an alternative viral vector vaccine candidate reported in the literature. Because nonreplicating subunit vaccines offer the possibility of formulation for cost-effective, long-term storage in biothreat reduction repositories, EIC is an attractive option for public health defense measures.



Related Articles
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
J Virol. 2006
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, et al. J Virol. 2006 Mar; 80(6):2738-46.
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
Vaccine. 2011
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
Konduru K, Bradfute SB, Jacques J, Manangeeswaran M, Nakamura S, Morshed S, Wood SC, Bavari S, Kaplan GG. Vaccine. 2011 Apr 5; 29(16):2968-77. Epub 2011 Feb 15.
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.
J Immunol. 2005
Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.
Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S. J Immunol. 2005 Jul 15; 175(2):1184-91.
Review Recent advances in Ebolavirus vaccine development.
Hum Vaccin. 2010
Review Recent advances in Ebolavirus vaccine development.
Richardson JS, Dekker JD, Croyle MA, Kobinger GP. Hum Vaccin. 2010 Jun; 6(6):439-49. Epub 2010 Jun 1.
Review Ebola virus: unravelling pathogenesis to combat a deadly disease.
Trends Mol Med. 2006
Review Ebola virus: unravelling pathogenesis to combat a deadly disease.
Hoenen T, Groseth A, Falzarano D, Feldmann H. Trends Mol Med. 2006 May; 12(5):206-15. Epub 2006 Apr 17.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.